Medpage Today on MSN14h
Big Comeback for Myeloma Drug; DIY Cancer Therapy; Gut Clues to Bladder CancerGSK announced that belantamab mafodotin (Blenrep) plus bortezomib (Velcade) and dexamethasone improved overall survival in ...
On Thursday, GSK plc (NYSE:GSK) released headline results from a planned interim analysis of the DREAMM-7 head-to-head phase ...
GSK has announced positive headline interim analysis outcomes from a Phase III trial, which is evaluating Blenrep (belantamab ...
UK drugmaker GSK might be trading lower following Thursday’s nomination of vaccine sceptic Robert F Kennedy Jr as the USA’s ...
LONDON, UK I 14, 2024 I GSK plc (LSE/NYSE: GSK) today announced positive headline results from a planned interim analysis of the DREAMM-7 ...
GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...
GSK plc (GSK, GSK.L), on Thursday, announced positive headline results from a planned interim analysis of the DREAMM-7 head-to-head ...
The pharma group reported top-line results from the DREAMM-7 study this morning, showing a greater benefit for Blenrep (belantamab mafodotin) compared to Genmab and Johnson & Johnson’s anti-CD37 ...
The data from the DREAMM-7 study shows that Blenrep (belantamab mafodotin) was more effective at extending overall survival (OS) than Genmab and Johnson & Johnson’s anti-CD37 therapy Darzalex ...
The leading AL Amyloidosis Companies such as Caelum Biosciences, Nexcella, Inc., HaemaLogiX Ltd., Prothena, ZENTALIS ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback